Hearing is a delicate sense that depends on the precise function of the inner ear. Certain medications can damage this system, leading to hearing loss or tinnitus. Among these are ototoxic diuretics, a group of drugs that can adversely affect the auditory system. This article examines how diuretics, particularly loop diuretics, can impact hearing, the underlying mechanisms, and how healthcare providers manage these risks.

What Are Ototoxic Diuretics?

Diuretics are commonly used to remove excess fluid from the body, often for conditions such as heart failure, kidney disease, and hypertension. While most diuretics are safe for hearing, a specific class known as ototoxic diuretics has the potential to cause temporary or permanent damage to the inner ear. The most notable ototoxic diuretics are loop diuretics, which include drugs such as furosemide, bumetanide, torsemide, and ethacrynic acid. Loop diuretics act on the ascending limb of the loop of Henle in the kidney, but they also affect the stria vascularis, the structure that maintains the ionic balance of the inner ear fluid.

Loop Diuretics and Hearing: The Connection

Loop diuretics are the diuretics most strongly associated with hearing disturbances. Hearing loss from these agents is often sudden, bilateral, and may be accompanied by vertigo or a feeling of ear fullness. The effect is typically dose-related and more common when the drug is given rapidly by intravenous injection, especially in patients with kidney failure or those concurrently receiving other ototoxic medications such as aminoglycoside antibiotics. Ethacrynic acid is considered the most ototoxic among the loop diuretics, while furosemide and others also carry a significant risk.

How Loop Diuretics Damage Hearing

The inner ear contains the cochlea, a spiral-shaped organ that converts sound vibrations into electrical nerve impulses. Within the cochlea is the stria vascularis, a nutrient-rich region that produces endolymph, a fluid with high potassium and low sodium concentrations. The electrical potential of the cochlea depends on this ionic composition. Loop diuretics inhibit the Na-K-2Cl cotransporter in the stria vascularis, the same transport protein they block in the kidney. This inhibition disrupts ion movement, causing swelling and dysfunction of the strial cells. As a result, the endocochlear potential drops, and the sensitivity of hair cells is markedly reduced. In many cases, the effect is reversible because the cells can recover once the drug is eliminated. However, with very high doses or prolonged exposure, irreversible damage may occur.

Risk Factors for Ototoxicity

Several factors increase the likelihood that a loop diuretic will cause hearing damage. These include:

• Rapid intravenous administration, which produces very high peak drug concentrations in the blood and inner ear.
• Impaired renal function, as reduced clearance leads to drug accumulation and prolonged exposure of the cochlea.
• Concurrent use of other ototoxic medications, especially aminoglycoside antibiotics, platinum-based chemotherapy agents, or salicylates.
• Pre-existing hearing loss, which may lower the threshold for injury that is clinically noticeable.
• Genetic variations in transporters or detoxification enzymes that make an individual more vulnerable.
• Age, with older adults often more susceptible to ototoxic injury.

Potential Preventive Measures and Clinical Management

Clinicians can take several steps to minimise the risk of loop diuretic-induced hearing loss. The most effective strategy is to use the lowest effective dose and to administer the drug by slow infusion or oral route when possible. Monitoring hearing function during prolonged therapy is also valuable, especially in patients with kidney failure or those receiving other ototoxic drugs. If signs of hearing impairment appear, healthcare providers might reduce the dose, switch to a non-loop diuretic, or choose a loop diuretic with lower ototoxic potential. It is important to note that not all diuretics are equal in this regard; thiazide and potassium-sparing diuretics are not typically associated with hearing loss unless severe electrolyte disturbances occur.

Conclusion

Ototoxic diuretics, particularly loop diuretics, represent a significant but often underrecognised cause of drug-induced hearing loss. Understanding the relationship between diuretics and hearing is essential for clinicians who prescribe these medications or who see patients with unexplained auditory symptoms. When loop diuretics are necessary, careful dosing and coordination with other treatments can help preserve hearing while still achieving fluid balance. For patients, early reporting of hearing changes is fundamental to preventing permanent damage. While the inner ear is vulnerable, heightened awareness and careful prescribing can significantly reduce the impact of these useful but potentially harmful drugs.